Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience.

Yang LiuWen LongZitong ZhangLixin MaiSijuan HuangBoji LiuWufei CaoJianhua WuFangjian ZhouYonghong LiLiru He

Published in: Radiation oncology (London, England) (2021)

cRT before resistance to abiraterone may improve survival in selected mCRPC patients: age ≤ 65 years old, chemotherapy-naïve, with a relatively low PSA level at the diagnosis of mCRPC and intermediate prognosis.

Keyphrases

prostate cancer
end stage renal disease
radical prostatectomy
ejection fraction
chronic kidney disease
locally advanced
squamous cell carcinoma
small cell lung cancer
peritoneal dialysis
prognostic factors
patient reported outcomes
radiation induced
patient reported